Imaging of the prostate-specific membrane antigen (PSMA) has become an important tool
for managing patients with recurrent prostate cancer, and one of the most frequently …

Context The clinical introduction of next-generation imaging methods and molecular
biomarkers (“radiogenomics”) has revolutionized the field of prostate cancer (PCa). While …

The impact of prostate-specific membrane antigen (PSMA) PET/CT on management of
prostate cancer (PCa) patients with biochemical recurrence (BCR) is well established …

Background Men with high-risk prostate cancer undergoing surgery likely recur due to
failure to completely excise regional and/or local disease. Objective The first-in-human …

Abstract Context Prostate cancer (PCa) is the most common solid organ malignancy in men
and is the third leading cause of cancer death. Accurate methods for the detection and …

Prostate-specific membrane antigen (PSMA) as a transmembrane protein is overexpressed
by prostate cancer (PC) cells and is accessible for binding antibodies or low-molecular …

Context Management of newly diagnosed prostate cancer (PCa) is guided in part by
accurate clinical staging. The role of imaging, including magnetic resonance imaging (MRI) …

Background Data regarding 2-(3-{1-carboxy-5-[(6-[18F] fluoro-pyridine 3-carbonyl)-amino]-
pentyl}-ureido)-pentanedioic acid (18F-DCFPyL) PET in primary staging of prostate cancer …

In nuclear medicine, theranostics (combining therapy and diagnostics in one platform) is
made possible through the utilization of radiopharmaceuticals for both therapeutic and …

Background Definitive radiation therapy (dRT) is an effective initial treatment of intermediate-
risk (IR) and high-risk (HR) prostate cancer (PCa). PSMA PET/CT is superior to standard of …